Literature DB >> 17541014

Restoration of W1282X CFTR activity by enhanced expression.

Steven M Rowe1, Karoly Varga, Andras Rab, Zsuzsa Bebok, Kevin Byram, Yao Li, Eric J Sorscher, John P Clancy.   

Abstract

Cystic fibrosis results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Premature termination codons represent a common minority of CFTR mutations, and are caused by base pair substitutions that produce abnormal stop codons in the coding sequence. Select aminoglycosides induce "translational readthrough" of premature stop codons and have been shown to restore full-length functional protein in a number of preclinical and clinical settings. We studied two well-described premature termination codons found in the distal open reading frame of CFTR, W1282X and R1162X, expressed in polarizing and nonpolarizing cells. Our findings indicate that W1282X CFTR-expressing cells demonstrate significantly greater CFTR activity when overexpressed compared with R1162X CFTR cells, even when truncated protein is the predominant form. In addition, our results show that the combination of stimulated expression and stop codon suppression produces additive effects on CFTR-mediated ion transport. These findings provide evidence that W1282X CFTR exhibits membrane localization and retained chloride channel function after enhanced expression, and suggest that patients harboring this mutation may be more susceptible to CFTR rescue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541014      PMCID: PMC1994229          DOI: 10.1165/rcmb.2006-0176OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  45 in total

1.  Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain 1 (NBD-1) and CFTR truncated within NBD-1 target to the epithelial plasma membrane and increase anion permeability.

Authors:  J P Clancy; J S Hong; Z Bebök; S A King; S Demolombe; D M Bedwell; E J Sorscher
Journal:  Biochemistry       Date:  1998-10-27       Impact factor: 3.162

Review 2.  Genotype-phenotype correlations in cystic fibrosis.

Authors:  E Kerem; B Kerem
Journal:  Pediatr Pulmonol       Date:  1996-12

3.  A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis.

Authors:  J E Mickle; M Macek; S B Fulmer-Smentek; M M Egan; E Schwiebert; W Guggino; R Moss; G R Cutting
Journal:  Hum Mol Genet       Date:  1998-04       Impact factor: 6.150

4.  Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line.

Authors:  D M Bedwell; A Kaenjak; D J Benos; Z Bebok; J K Bubien; J Hong; A Tousson; J P Clancy; E J Sorscher
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

5.  Activation of DeltaF508 CFTR in an epithelial monolayer.

Authors:  Z Bebök; C J Venglarik; Z Pánczél; T Jilling; K L Kirk; E J Sorscher
Journal:  Am J Physiol       Date:  1998-08

6.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations.

Authors:  M Howard; R A Frizzell; D M Bedwell
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

7.  Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells.

Authors:  T Shoshani; E Kerem; A Szeinberg; A Augarten; Y Yahav; D Cohen; J Rivlin; A Tal; B Kerem
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Microtubule-dependent transport of secretory vesicles visualized in real time with a GFP-tagged secretory protein.

Authors:  I Wacker; C Kaether; A Krömer; A Migala; W Almers; H H Gerdes
Journal:  J Cell Sci       Date:  1997-07       Impact factor: 5.285

9.  Partitioning of the Golgi apparatus during mitosis in living HeLa cells.

Authors:  D T Shima; K Haldar; R Pepperkok; R Watson; G Warren
Journal:  J Cell Biol       Date:  1997-06-16       Impact factor: 10.539

10.  The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli.

Authors:  E S Poole; C M Brown; W P Tate
Journal:  EMBO J       Date:  1995-01-03       Impact factor: 11.598

View more
  39 in total

1.  Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1.

Authors:  Martin H Ruwald; Xiaorong Xu Parks; Arthur J Moss; Wojciech Zareba; Jayson Baman; Scott McNitt; Jorgen K Kanters; Wataru Shimizu; Arthur A Wilde; Christian Jons; Coeli M Lopes
Journal:  Heart Rhythm       Date:  2015-08-28       Impact factor: 6.343

Review 2.  Potential beneficial effects of butyrate in intestinal and extraintestinal diseases.

Authors:  Roberto Berni Canani; Margherita Di Costanzo; Ludovica Leone; Monica Pedata; Rosaria Meli; Antonio Calignano
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

3.  Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators.

Authors:  Louise C Pyle; Annette Ehrhardt; Lisa High Mitchell; Lijuan Fan; Aixia Ren; Anjaparavanda P Naren; Yao Li; J P Clancy; Graeme B Bolger; Eric J Sorscher; Steven M Rowe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-01       Impact factor: 5.464

Review 4.  Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Authors:  Mohamad R Chaaban; Alexandra Kejner; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

5.  New trends in aminoglycosides use.

Authors:  Marina Y Fosso; Yijia Li; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

Review 6.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

7.  Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

Authors:  Puay-Wah Phuan; Jung-Ho Son; Joseph-Anthony Tan; Clarabella Li; Ilaria Musante; Lorna Zlock; Dennis W Nielson; Walter E Finkbeiner; Mark J Kurth; Luis J Galietta; Peter M Haggie; Alan S Verkman
Journal:  J Cyst Fibros       Date:  2018-06-12       Impact factor: 5.482

Review 8.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

9.  Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.

Authors:  Mark T Dransfield; Andrew M Wilhelm; Brian Flanagan; Clifford Courville; Sherry L Tidwell; S Vamsee Raju; Amit Gaggar; Chad Steele; Li Ping Tang; Bo Liu; Steven M Rowe
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

10.  The effect of gentamicin-induced readthrough on a novel premature termination codon of CD18 leukocyte adhesion deficiency patients.

Authors:  Amos J Simon; Atar Lev; Baruch Wolach; Ronit Gavrieli; Ninette Amariglio; Ester Rosenthal; Ephraim Gazit; Eran Eyal; Gideon Rechavi; Raz Somech
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.